Zivo Bioscience Reports Revenue Growth but Faces Significant Losses and Liquidity Challenges

Zivo Bioscience, Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $65,625, a significant increase from $31,500 in the same period last year. For the nine months ending September 30, 2025, the company generated $119,025 in revenue, up from $67,220 in the prior year. The increase in revenue is attributed to higher sales volumes of the company's dried algal biomass product, which is marketed as a food ingredient. Despite the revenue growth, Zivo Bioscience continues to face substantial losses, reporting a net loss of $1,033,056 for the quarter and $6,884,474 for the nine-month period, although these figures represent a reduction in losses compared to $2,268,597 and $11,783,451, respectively, in the previous year.

The company's financial position has changed markedly, with total current assets decreasing to $281,399 as of September 30, 2025, down from $1,635,442 at the end of 2024. This decline is primarily due to a significant reduction in cash reserves, which fell to $57,222 from $1,542,442. Current liabilities, however, increased to $3,614,268 from $2,041,823, leading to a total liabilities figure of $3,846,055, compared to $2,158,020 at the end of the previous fiscal year. The accumulated deficit has also widened to $143,851,025, reflecting ongoing operational challenges.

Operationally, Zivo Bioscience has made strategic moves, including entering into a convertible loan agreement for up to $2 million, of which $250,000 has been drawn down. The company also engaged in several exchange agreements, resulting in the issuance of 146,660 shares of common stock in exchange for the cancellation of certain revenue-sharing rights. These agreements are part of Zivo's efforts to streamline its financial obligations and enhance its capital structure. The company has also focused on reducing general and administrative expenses, which fell to $836,187 for the quarter, down from $1,943,126 in the prior year, largely due to decreased labor costs and professional services.

Looking ahead, Zivo Bioscience faces significant liquidity challenges, with cash reserves insufficient to cover operational expenses for the next twelve months. The company estimates a need for approximately $6 million in cash to fund its basic operations, excluding research and development initiatives. Management has expressed substantial doubt about the company's ability to continue as a going concern without securing additional funding through equity or debt financing. The company plans to pursue strategic partnerships for product development and commercialization while continuing to develop its algal-based products for both human and animal health markets.